Fundraising FoxNostopharma
Potomac, US · Maryland LLC · 2 known investors
Find your way into Nostopharma
Sign up to see every warm intro you have to Nostopharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nostopharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Nostopharma develops targeted nanodelivery technology and advanced molecular interventions for bone and soft tissue disorders, using precision medicine approaches to repurpose existing drugs. The company serves clinicians treating patients with conditions like heterotopic ossification and cartilage damage.
Founders & leadership
EV
Ekaterina Vert-WongNamed on SEC filing
JG
Jelena Gvozdenovic-JeremicNamed on SEC filing
Investors · 2
Maryland TEDCOlisted by Maryland TEDCOColumbia · $500K – $1.5M
How we know: Maryland TEDCO's portfolio page · Not right? Tell us
TEDCOlisted by TEDCOColumbia
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$500K disclosed across 2 rounds · 2023–2024
▶$250KraisedSep 2024 · 1 investors · Other Health CareRule 506(b)
▶$250KraisedSep 2024 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ekaterina Vert-WongExecutive Officer, Director
- Jelena Gvozdenovic-JeremicExecutive Officer
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Sep 2024
- Incorporated
- Limited Liability Company, Maryland
- Federal exemptions
- 06b
▶$250KraisedJun 2023 · 1 investors · OtherRule 506(b)
▶$250KraisedJun 2023 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Ekaterina Vert-WongExecutive Officer, Director
- Jelena JeremicExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Jun 2023
- Incorporated
- Limited Liability Company, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Nostopharma do?
- Nostopharma develops targeted nanodelivery technology and advanced molecular interventions for bone and soft tissue disorders, using precision medicine approaches to repurpose existing drugs. The company serves clinicians treating patients with conditions like heterotopic ossification and cartilage damage.
- Who are Nostopharma's investors?
- Nostopharma's investors include Maryland TEDCO, TEDCO.
- How much funding has Nostopharma raised?
- Nostopharma has disclosed $500K raised across 2 rounds.
- Where is Nostopharma headquartered?
- Nostopharma is headquartered in Potomac, US.